| Literature DB >> 31213037 |
David Miko1, Carmen Costache2, Horațiu Alexandru Colosi3, Vlad Neculicioiu4, Ioana Alina Colosi5.
Abstract
Background and objectives: Health systems all over the world are confronted with an alarming rise of cases in which individuals hesitate, delay, and even refuse vaccination, despite availability of quality vaccine services. In order to mitigate and combat this phenomenon, which are now defined by the World Health Organization (WHO) as vaccine hesitancy (VH), we must first understand the factors that lead to its occurrence in an era characterized by wide access to safe and effective vaccines. To achieve this, we conducted field testing of the Vaccine Hesitancy Scale (VHS), as it was developed by the Strategic Advisory Group of Experts Working Group (SAGE WG), in Cluj-Napoca city, Cluj County, Romania. The scale is designed to quantify VH prevalence in a population, establish which vaccines generate the highest percentage of hesitancy, and allow a qualitative assessment of the individual's reasons for hesitance. Materials andEntities:
Keywords: HPV; MMR; influence of media; measles outbreak; qualitative thematic analysis; vaccine acceptance; vaccine hesitancy
Mesh:
Year: 2019 PMID: 31213037 PMCID: PMC6631779 DOI: 10.3390/medicina55060282
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Matrix of Determinants (MxDt) of vaccine hesitancy (VH).
|
|
Communication & media environment Influential leaders, immune Historical influences Religion/culture/gender/socio-economic Politics/policies Geographical barriers Perception of pharmaceutical industry |
|
|
Personal, family, and/or community member experience with vaccination, including pain Beliefs, attitudes Knowledge/awareness Health system and providers-trust and personal experience Risk/benefits (perceived, heuristics) Immunization as a social norm |
|
|
Risk/benefits (epidemiological and scientific evidence) Introduction of a new vaccine Mode of administration Design of vaccination program Reliability and/or source of vaccine Vaccination schedule Costs Strength of recommendation |
Inter-rater reliability measures for the items of the MxDt of VH.
| Item | Percent Agreement | Scott’s Pi | Cohen’s Kappa | Krippendorff’s Alpha | No. Agreements | No. Disagreements |
|---|---|---|---|---|---|---|
|
| 94.83 | 0.90 | 0.90 | 0.90 | 660 | 36 |
|
| 95.55 | 0.88 | 0.88 | 0.88 | 665 | 31 |
|
| 100.00 | 1 | 1 | 1 | 696 | 0 |
|
| 99.71 | 0.95 | 0.95 | 0.95 | 694 | 2 |
|
| 97.84 | 0.60 | 0.60 | 0.60 | 681 | 15 |
|
| 99.86 | 0.67 | 0.67 | 0.67 | 695 | 1 |
|
| 92.96 | 0.81 | 0.81 | 0.81 | 647 | 49 |
|
| 97.41 | 0.54 | 0.54 | 0.54 | 678 | 18 |
|
| 94.54 | 0.87 | 0.87 | 0.88 | 658 | 38 |
|
| 94.40 | 0.89 | 0.89 | 0.89 | 657 | 39 |
|
| 96.12 | 0.79 | 0.79 | 0.79 | 669 | 27 |
|
| 89.51 | 0.79 | 0.79 | 0.79 | 623 | 73 |
|
| 98.13 | 0.86 | 0.86 | 0.86 | 683 | 13 |
|
| 91.81 | 0.81 | 0.81 | 0.81 | 639 | 57 |
|
| 99.71 | 0.83 | 0.83 | 0.83 | 694 | 2 |
|
| 99.57 | 0.85 | 0.85 | 0.86 | 693 | 3 |
|
| 100.00 | 1 | 1 | 1 | 696 | 0 |
|
| 98.99 | 0.46 | 0.46 | 0.46 | 689 | 7 |
|
| 98.71 | 0.85 | 0.85 | 0.85 | 687 | 9 |
|
| 99.71 | 0.86 | 0.86 | 0.86 | 694 | 2 |
|
| 96.12 | 0.84 | 0.84 | 0.84 | 669 | 27 |
|
| 99.14 | 0.83 | 0.83 | 0.83 | 690 | 6 |
Deductive Thematic Analysis.
| SAGE WG Vaccine Hesitancy Model * | |||||
|---|---|---|---|---|---|
| Contextual Influences | Individual and Group Influences | Vaccine and Vaccination-Specific Issues | |||
| Items | Iterations | Items | Iterations | Items | Iterations |
| 1 | 314 | 8 | 27 | 14 | 477 |
| 2 | 165 | 9 | 225 | 15 | 7 |
| 3 | 0 | 10 | 303 | 16 | 10 |
| 4 | 22 | 11 | 68 | 17 | 0 |
| 5 | 23 | 12 | 377 | 18 | 7 |
| 6 | 2 | 13 | 46 | 19 | 31 |
| 7 | 177 | 20 | 7 | ||
| 21 | 101 | ||||
| TOTAL (%) | 703 (29.2) | TOTAL (%) | 1046 (43.5) | TOTAL (%) | 640 (26.6) |
* Total statements: 697. Statements considered “not codable”: 17. SAGE WG: Strategic Advisory Group of Experts Working Group.